CY1111293T1 - Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης - Google Patents

Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης

Info

Publication number
CY1111293T1
CY1111293T1 CY20101101199T CY101101199T CY1111293T1 CY 1111293 T1 CY1111293 T1 CY 1111293T1 CY 20101101199 T CY20101101199 T CY 20101101199T CY 101101199 T CY101101199 T CY 101101199T CY 1111293 T1 CY1111293 T1 CY 1111293T1
Authority
CY
Cyprus
Prior art keywords
herpes virus
connector
hvem
fusion proteins
medium entry
Prior art date
Application number
CY20101101199T
Other languages
English (en)
Inventor
Carl F Ware
Original Assignee
La Jolla Institute For Allergy And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Institute For Allergy And Immunology filed Critical La Jolla Institute For Allergy And Immunology
Publication of CY1111293T1 publication Critical patent/CY1111293T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Προβλέπεται κάποιος καινοτόμος πολυπεπτιδικός συνδέτης, p30 ή LIGHT, για το μεσολαβητή εισόδου του ιού του έρπητα, HVEM. Ο p30 χρησιμεύει για τη ρύθμιση των ανοσοαπαντήσεων και την αναστολή της λοίμωξης ή/και του επακόλουθου πολλαπλασιασμού από ερπητοϊό. Προβλέπονται επίσης πρωτεΐνες σύντηξης του HVEM. Προβλέπονται επίσης μέθοδοι για την θεραπευτική αγωγή ατόμων με διαταραχές των λεμφικών κυττάρων, όγκους, αυτοάνοσα νοσήματα, φλεγμονώδεις διαταραχές όσων πάσχουν ή υπάρχει υποψία ότι πάσχουν από κάποια λοίμωξη του ερπητοϊού, χρησιμοποιώντας τον p30 και τις πρωτεΐνες σύντηξης της εφεύρεσης.
CY20101101199T 2000-04-12 2010-12-29 Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης CY1111293T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54909600A 2000-04-12 2000-04-12
EP05023967A EP1674575B1 (en) 2000-04-12 2001-04-11 Ligand for herpes simplex virus entry mediator and methods of use

Publications (1)

Publication Number Publication Date
CY1111293T1 true CY1111293T1 (el) 2015-08-05

Family

ID=24191643

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101199T CY1111293T1 (el) 2000-04-12 2010-12-29 Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης

Country Status (10)

Country Link
EP (2) EP1674575B1 (el)
JP (1) JP2003531152A (el)
AT (2) ATE483807T1 (el)
AU (1) AU5338701A (el)
CA (1) CA2406132C (el)
CY (1) CY1111293T1 (el)
DE (2) DE60129010T2 (el)
DK (1) DK1674575T3 (el)
ES (1) ES2352742T3 (el)
PT (1) PT1674575E (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010692A1 (ja) * 2005-07-19 2007-01-25 Japan Science And Technology Agency Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
US11708406B2 (en) 2020-04-01 2023-07-25 Avalo Therapeutics, Inc. Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
CN111991551A (zh) * 2020-07-31 2020-11-27 中国人民解放军海军军医大学 Traf3半胱氨酸突变体在制备抗病毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP2000508522A (ja) * 1996-03-22 2000-07-11 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド アポトーシス誘導分子ｉｉ
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
DE69730607T2 (de) * 1996-07-19 2005-01-27 Takeda Chemical Industries, Ltd. Fas ligand ähnliches protein, seine herstellung und verwendung
IL129527A (en) * 1996-10-25 2006-12-10 Biogen Idec Inc Pharmaceutical preparations containing soluble lymphoxine-beta receptors
WO1998018824A1 (en) * 1996-10-30 1998-05-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like 2
AU5516898A (en) * 1996-12-12 1998-07-03 Genentech Inc. Hvem polypeptides and uses thereof
EP1009431A4 (en) * 1997-05-12 2000-09-27 Smithkline Beckman Corp ANTIBODIES AGAINST THE TYPE 2 (TR2) HUMAN TUMORNESCROSE FACTOR RECEPTOR
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6346388B1 (en) * 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011662A1 (en) 1997-09-05 1999-03-11 Millennium Biotherapeutics, Inc. Novel molecules of the tnfr-ligand-related protein family and uses thereof
WO1999042584A1 (en) * 1998-02-20 1999-08-26 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
AU5568799A (en) * 1998-08-18 2000-03-14 Northwestern University Peptides for inhibition of herpes simplex virus entry
JP2002529051A (ja) 1998-09-03 2002-09-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヘルペスウイルス侵入メディエーター関連タンパク質ファミリーの新規分子およびその使用
KR100888832B1 (ko) * 1998-10-09 2009-03-17 바이오겐 아이덱 엠에이 인코포레이티드 림프독소 베타 경로의 차단에 의한 바이러스-유도성 전신 쇼크 및 호흡 장애의 반전
EP1161261A1 (en) * 1999-03-11 2001-12-12 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use

Also Published As

Publication number Publication date
CA2406132C (en) 2012-07-03
PT1674575E (pt) 2010-12-06
ATE483807T1 (de) 2010-10-15
DK1674575T3 (da) 2010-11-29
EP1274840A2 (en) 2003-01-15
EP1674575A2 (en) 2006-06-28
EP1274840B1 (en) 2007-06-20
ES2352742T3 (es) 2011-02-22
CA2406132A1 (en) 2001-10-25
EP1674575A3 (en) 2007-08-08
DE60129010T2 (de) 2008-02-28
DE60143231D1 (de) 2010-11-18
AU5338701A (en) 2001-10-30
EP1674575B1 (en) 2010-10-06
ATE365214T1 (de) 2007-07-15
DE60129010D1 (de) 2007-08-02
JP2003531152A (ja) 2003-10-21

Similar Documents

Publication Publication Date Title
CY1111293T1 (el) Συνδετης για μεσολαβητη εισοδου του ιου του απλου ερπητα και μεθοδοι χρησης
DE69842096D1 (de) Ligand des zelleintritt-vermittelnden proteins von herpes simplex virus und methoden zu dessen verwendung
ATE280178T1 (de) Langwellig fluorezierende proteine
ATE461938T1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
ATE172984T1 (de) Nukleinsäuren-bindende oligomere mit n- verzweigung für therapie und diagnostik
DK19290D0 (da) Molekulaer samling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
DK0526452T3 (da) Hybridimmunoglobuliner
ATE268818T1 (de) Ctla4-mutantmoleküle und deren verwendung
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
WO2001079496A3 (en) Ligand for herpes simplex virus entry mediator and methods of use
FR2806739B1 (fr) Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
DE59408308D1 (de) Nukleinsäure-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
EP1012603A4 (en) FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND METHODS OF USE
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ATE528392T1 (de) Neues protein und dessen dns
NO970130D0 (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao